RhEumatiC Heart diseAse Genetics (RECHARGE)

• ClinicalTrials.gov Identifier: NCT02118818
• Recruitment Status: Recruiting
• First Posted: April 21, 2014
• Last Update Posted: February 8, 2023
• Sponsor: Brigham and Women's Hospital
• Collaborator: National University, Rwanda
• Information provided by (Responsible Party): Jochen Daniel Muehlschlegel, MD, Brigham and Women's Hospital

Study Description

Brief Summary:

Rheumatic fever (RF) is an autoimmune disease that is mediated by the cellular and humoral immune response that follows an untreated pharyngeal Streptococcus pyogenes infection. The most serious complication is rheumatic heart disease (RHD), one of the most common problems facing children and young adults worldwide, which leads to chronic valvular lesions. It is estimated that 60% of all acute rheumatic fever cases will develop RHD.

The pathogenesis of RHD is complex with both environmental and genetic factors contributing to its etiology. The investigators know little about the genetic etiology, cellular events and modifiers of progression of RHD, and there exists a wide range of disease severity and progression to severe valve pathology.

Thus, the investigators will study the genetics of RHD in Rwanda, a country with a very high incidence of RHD, using a combination of next-generation targeted exome capture, transcriptomics, and expressed quantitative trait loci (eQTL) analysis.

Condition or disease	Intervention/treatment
Rheumatic Heart Disease	Genetic: Next generation sequencing

Detailed Description:

There are an estimated 2.4 million children between 5 and 14 years of age affected by RF and/or RHD in developing countries of the world, approximately one million of whom live in sub-Saharan Africa (>40%) (1). A systematic review of prevalence studies found exceptionally high rates of RHD in sub-Saharan Africa, with the highest level found at 30.4 cases per 1000 children in Mozambique (2,3,4,5). At present, no specific treatment for rheumatic heart disease exists other than for its complications, including heart failure, atrial fibrillation, ischemic embolic events, and infective endocarditis. Medical treatment (other than antibiotic prophylaxis) has shown little evidence of slowing the progression of the disease. Medical heart failure treatment is given when patients become symptomatic, and includes mainly β blockers, angiotensin converting- enzyme inhibitor therapies, or a combination of both, as tolerated, and symptomatic treatments such as diuretics. Patients with atrial fibrillation need rate or rhythm control and anticoagulation with warfarin if at high risk of embolic complications. Rheumatic heart disease is a major cause of infective endocarditis in African countries.

North American and European guidelines have considerably reduced the number of heart disorders needing antibiotic prophylaxis to prevent infective endocarditis. Whether guidelines issued from developed regions can be safely applied to developing countries is debatable, and further studies are warranted. Pregnancy in patients with rheumatic heart disease is a challenge, and is associated with high morbidity and mortality. Antenatal consultation with support from cardiology and obstetrics clinics should be done to Provide contraception, counseling, treatment planning before start of pregnancy, and planning for patients with moderate to severe disease who are already pregnant (e.g. caesarean section).

Rheumatic fever (RF) is an autoimmune disease that is mediated by the cellular and humoral immune response that follows an untreated pharyngeal Streptococcus pyogenes infection. The most serious complication is rheumatic heart disease (RHD), one of the most common problems facing children and young adults worldwide, which leads to chronic valvular lesions. It is estimated that 60% of all acute rheumatic fever cases will develop RHD. Each year, there are >280,000 new cases and almost as many deaths from RHD, with a worldwide prevalence of >15 million, of which almost 20% are children aged 5-14 years. The worldwide mortality from RHD is 1.5% annually, compared with an overall mortality of 0.26% for all other cardiovascular diseases in the US3. 79% of all RHD cases come from less developed countries with the highest prevalence in sub-Saharan Africa and Pacific and indigenous Australia/New Zealand (~3-7 cases per 1,000).

The pathogenesis of RHD is complex with both environmental and genetic factors contributing to its etiology, though molecular mimicry between components of S. pyogenes and human heart tissue appear to be a central problem. A clear correlation exists between disease prevalence and lower socioeconomic status in developing countries, while the disease prevalence in developed countries continues to decline. However, the manifestation of acute rheumatic fever in only a subset of children with untreated throat infection by S. pyogenes, familial clustering, and high concordance of RHD among monozygous twins provides strong evidence for genetic determinants for disease susceptibility. Yet the investigators know little about the genetic etiology, cellular events and modifiers of progression of RHD, and there exists a wide range of disease severity and progression to severe valve pathology.

Study Design

• Study Type: Observational [Patient Registry]
• Estimated Enrollment: 1000 participants
• Observational Model: Case-Control
• Time Perspective: Prospective
• Target Follow-Up Duration: 5 Years
• Official Title: Next Generation Sequencing Approach to the Study of Rheumatic Heart Disease
• Study Start Date: February 2014
• Estimated Primary Completion Date: July 2024
• Estimated Study Completion Date: July 2024

Groups and Cohorts

Group/Cohort	Intervention/treatment
NO rheumatic heart disease by echo; There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.	Genetic: Next generation sequencing; There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
Rheumatic heart disease by echo; There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.	Genetic: Next generation sequencing; There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.

Outcome Measures

Primary Outcome Measures :

1. Echocardiographic signs of rheumatic heart disease [ Time Frame: 3 years ]
   All patients enrolled will have had an echocardiogram of their heart to assess for signs of rheumatic heart disease according to WHF criteria. The investigators will perform next generation sequencing on their tissue samples and perform a combination of whole exome or genotyping array on their DNA samples. The goal is to identify variants in those patients with severe disease compared to age, gender, socioeconomic, geographically matched controls without echocardiography signs of RHD.

Biospecimen Retention:   Samples With DNA

The investigators are collecting blood for DNA analysis from all subjects as well as heart valve tissue from subjects who undergo cardiac surgery.

Eligibility Criteria

• Ages Eligible for Study: 5 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes
• Sampling Method: Probability Sample

Study Population

The investigators will include patients aged between 5-40 years in Rwanda presenting with an initial diagnosis of RHD and whose echocardiographic findings meet the criteria for definite RHD. World Heart Federation's criteria for echocardiographic diagnosis of definite RHD will be used, utilizing a combination of pathological criteria and morphological features.

Criteria

Inclusion Criteria:

• Clinical and echocardiographic signs of RHD using WHF criteria

Exclusion Criteria:

• Congenital heart disease

Contacts and Locations

Contacts

Contact: Jochen D Muehlschlegel, MD, MMSc; +1 617 732 7330; jmuehlschlegel@partners.org

Contact: Leon Mutesa, MD PhD; +250 78 845 10 13; lmutesa@nur.ac.rw

Locations

Rwanda

University of Rwanda; Recruiting

Kigali, Rwanda

Contact: Leon Mutesa, MD, PhD +250 78 845 10 13 lmutesa@nur.ac.rw

Principal Investigator: Leon Mutesa, MD, PhD

Sponsors and Collaborators

Brigham and Women's Hospital

National University, Rwanda

Investigators

• Principal Investigator: Jochen D Muehlschlegel, MD MMSc; Brigham and Women's Hospital, Harvard Medical School

More Information

Additional Information:

• Responsible Party: Jochen Daniel Muehlschlegel, MD, Associate Professor of Anesthesia, Brigham and Women's Hospital
• ClinicalTrials.gov Identifier: NCT02118818
• Other Study ID Numbers: 2013P002682/BWH
• First Posted: April 21, 2014
• Last Update Posted: February 8, 2023
• Last Verified: February 2023

Additional relevant MeSH terms:

Rheumatic Heart Disease; Rheumatic Diseases; Heart Diseases; Cardiovascular Diseases; Musculoskeletal Diseases; Connective Tissue Diseases; Rheumatic Fever; Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections